Executive Management

Education:
University of Copenhagen - M.Sc., Pharmacy
Smartly School of Business - MBA

Jeppe Ragnar Andersen joined Nordic Bioscience in 2007 and became Head of Clinical Development in 2010. Jeppe was the CEO of NBCD A/S from 2014-2022, and has now transitioned into the position as Group CEO of Sanos Group A/S.

Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.

He has headed the successful merging of two clinical development departments and an expansion of the department with highly motivated employees from 3 employees to 30 employees.

Education:
Copenhagen Business School – Masters of Accounting and Auditing

Henning Heiberg Andersen joined NBCD A/S in the beginning of 2021.

Henning is an experienced CFO with a career spanning five countries. He has served in senior executive finance roles in both private and public companies and has extensive experience with private equity operations.

Education:
University of Copenhagen - M.Sc., Pharmacy

Asger R. Bihlet joined Nordic Bioscience Clinical Development in 2013 and assumed the position as Medical Director in 2014. In 2021 he transitioned into his current position as the Chief Scientific Officer for Sanos Group A/S.

Asger has wide experience from several areas of the pharmaceutical industry with previous positions including 6 years as Head of Regulatory Affairs and later as Medical Advisor within the fields of cardiovascular diseases and oncology during which he has played an integral part in the design, initiation and wrap-up of several clinical projects. Asger currently leads the Medical Affairs activities in Nordic Bioscience Clinical Development, including heading the pharmacovigilance and regulatory affairs activities.

Asger is actively researching and publishing in the fields of osteoarthritis with a particular focus on optimizing clinical trial design and outcome.

Education:
University of Copenhagen - M.Sc., Pharmacy

Sara Daugaard Popik joined Nordic Bioscience in 2011 and became Clinical Operations Director in 2016.

Sara is actively focusing on performing better, cheaper and smarter clinical operational set ups to conduct efficient clinical trials within the field of especially osteoarthritis. Over the years, Sara has been involved on an operational and management level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.

She has headed the successful expansion of the Clinical Operations Department and NBCD Quality Management System, including implementation of Risk Based Monitoring and various computerized systems since her start in the organization almost 10 years ago.

In 2022, Sara was appointed Managing Director for NBCD.

Education:
University of Copenhagen - M.Sc., Pharmacy

Casper Clemmensen joined NBCD in 2016 as Clinical Trial Leader, transitioned into the position as Business Development Director in 2019 and was in 2022 appointed Chief Commercial Officer, responsible for all sales and marketing efforts at Sanos Group A/S.

Casper has a longstanding background of 13 years working with clinical development across pharma and biotech headquarter positions before joining NBCD in 2016. Over the years, Casper has gained unique insight to the different actors of the pharmaceutical industry which has led to a profound understanding of current and future NBCD partners resulting in strong strategic and scientific alliances.

“The ultimate goal of our partnerships is to help patients with osteoarthritis and address one of the largest unmet medical needs.”

Education:
University of Copenhagen - M.Sc., Pharmacy

Christoffer von Sehested joined NBCD as Clinical Operations Director in 2020, originally covering Sara’s maternity leave. In 2022, Christoffer was appointed the position as Chief Innovation Officer for the Sanos Group - responsible for Strategic initiatives and M&A integration.

Christoffer brings 20 years of experience with him and has been involved in 30 trials, including 2 products from phase 2 to the market. He has handled numerous inspections from FDA and EMA, and the last 5 years he has spent coordinating data collection, statistical programming and preparing data for submission. Before joining NBCD, Christoffer held the position as Senior Director Data Management and Biostatistics at KLIFO.

“I use my experience to span the gap between clinical operations and data management avoiding pitfalls arising from lack of overview of the entire data process from trial design to reporting.”